Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study

Sam Sollie; Aida Santaolalla; Dominique S. Michaud; Debashis Sarker; Sophia N. Karagiannis; Debra H. Josephs; Niklas Hammar; Goran Walldius; Hans Garmo; Lars Holmberg; Ingmar Jungner; Mieke Van Hemelrijck

doi:10.3389/fonc.2020.00263

Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study

Sam Sollie, Aida Santaolalla^*, Dominique S. Michaud, Debashis Sarker, Sophia N. Karagiannis, Debra H. Josephs, Niklas Hammar, Goran Walldius, Hans Garmo, Lars Holmberg, Ingmar Jungner, Mieke Van Hemelrijck

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

163 Downloads (Pure)

Abstract

Background: Emerging evidence points to potential roles of the humoral immune responses in the development of pancreatic cancer. Epidemiological studies have suggested involvement of viral and bacterial infections in pancreatic carcinogenesis. Experimental studies have reported high expression levels of antigens in pancreatic cancer cells. Therefore, we aimed to investigate the role of different components of humoral immunity in the context of pancreatic cancer. We evaluated associations between pre-diagnostic serum markers of the overall humoral immune system [immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM)], and the risk of pancreatic cancer in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) study. Methods: We selected all participants (≥20 years old) with baseline measurements of IgA, IgG or IgM (n = 41,900, 136,221, and 29,919, respectively). Participants were excluded if they had a history of chronic pancreatitis and individuals were free from pancreatic cancer at baseline. Multivariate Cox proportional hazards regression was used to estimate risk of pancreatic cancer for medical cut-offs of IgA, IgG, and IgM. Results: Compared to the reference level of 6.10–14.99 g/L, risk of pancreatic cancer was elevated among those with IgG levels <6.10 g/L [HR: 1.69 (95% CI 0.99–2.87)], and an inverse association was observed among those with IgG levels ≥15.00 g/L [0.82 (95% CI 0.64–1.05); Ptrend = 0.027]. The association appeared to be stronger for women than men [HR: 0.64 (95% CI 0.43–0.97) and 0.95 (95% CI 0.69–1.29), respectively]. No associations were observed with IgA or IgM. Conclusion: An inverse association was observed between pre-diagnostic serum levels of IgG and risk of pancreatic cancer. Our findings highlight the need to further investigate the role of immune response in pancreatic cancer etiology.

Original language	English
Article number	263
Pages (from-to)	263
Journal	Frontiers in oncology
Volume	10
DOIs	https://doi.org/10.3389/fonc.2020.00263
Publication status	Published - 28 Feb 2020

Keywords

AMORIS
IgA
IgG
IgM
immune system and cancer
pancreatic cancer
serum immunoglobulin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2020.00263

Serum immunoglobulin G is_SOLLIE_Accepted14February2020_GOLD AAMAccepted author manuscript, 386 KBLicence: CC BY

Cite this

Sollie, S., Santaolalla, A., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Walldius, G., Garmo, H., Holmberg, L., Jungner, I., & Van Hemelrijck, M. (2020). Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. Frontiers in oncology, 10, 263. Article 263. https://doi.org/10.3389/fonc.2020.00263

@article{8187704488a64e32b105b033245023d6,

title = "Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study",

abstract = "Background: Emerging evidence points to potential roles of the humoral immune responses in the development of pancreatic cancer. Epidemiological studies have suggested involvement of viral and bacterial infections in pancreatic carcinogenesis. Experimental studies have reported high expression levels of antigens in pancreatic cancer cells. Therefore, we aimed to investigate the role of different components of humoral immunity in the context of pancreatic cancer. We evaluated associations between pre-diagnostic serum markers of the overall humoral immune system [immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM)], and the risk of pancreatic cancer in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) study. Methods: We selected all participants (≥20 years old) with baseline measurements of IgA, IgG or IgM (n = 41,900, 136,221, and 29,919, respectively). Participants were excluded if they had a history of chronic pancreatitis and individuals were free from pancreatic cancer at baseline. Multivariate Cox proportional hazards regression was used to estimate risk of pancreatic cancer for medical cut-offs of IgA, IgG, and IgM. Results: Compared to the reference level of 6.10–14.99 g/L, risk of pancreatic cancer was elevated among those with IgG levels <6.10 g/L [HR: 1.69 (95% CI 0.99–2.87)], and an inverse association was observed among those with IgG levels ≥15.00 g/L [0.82 (95% CI 0.64–1.05); Ptrend = 0.027]. The association appeared to be stronger for women than men [HR: 0.64 (95% CI 0.43–0.97) and 0.95 (95% CI 0.69–1.29), respectively]. No associations were observed with IgA or IgM. Conclusion: An inverse association was observed between pre-diagnostic serum levels of IgG and risk of pancreatic cancer. Our findings highlight the need to further investigate the role of immune response in pancreatic cancer etiology.",

keywords = "AMORIS, IgA, IgG, IgM, immune system and cancer, pancreatic cancer, serum immunoglobulin",

author = "Sam Sollie and Aida Santaolalla and Michaud, {Dominique S.} and Debashis Sarker and Karagiannis, {Sophia N.} and Josephs, {Debra H.} and Niklas Hammar and Goran Walldius and Hans Garmo and Lars Holmberg and Ingmar Jungner and {Van Hemelrijck}, Mieke",

note = "Copyright {\textcopyright} 2020 Sollie, Santaolalla, Michaud, Sarker, Karagiannis, Josephs, Hammar, Walldius, Garmo, Holmberg, Jungner and Van Hemelrijck.",

year = "2020",

month = feb,

day = "28",

doi = "10.3389/fonc.2020.00263",

language = "English",

volume = "10",

pages = "263",

journal = "Frontiers in oncology",

issn = "2234-943X",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study

AU - Sollie, Sam

AU - Santaolalla, Aida

AU - Michaud, Dominique S.

AU - Sarker, Debashis

AU - Karagiannis, Sophia N.

AU - Josephs, Debra H.

AU - Hammar, Niklas

AU - Walldius, Goran

AU - Garmo, Hans

AU - Holmberg, Lars

AU - Jungner, Ingmar

AU - Van Hemelrijck, Mieke

PY - 2020/2/28

Y1 - 2020/2/28

N2 - Background: Emerging evidence points to potential roles of the humoral immune responses in the development of pancreatic cancer. Epidemiological studies have suggested involvement of viral and bacterial infections in pancreatic carcinogenesis. Experimental studies have reported high expression levels of antigens in pancreatic cancer cells. Therefore, we aimed to investigate the role of different components of humoral immunity in the context of pancreatic cancer. We evaluated associations between pre-diagnostic serum markers of the overall humoral immune system [immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM)], and the risk of pancreatic cancer in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) study. Methods: We selected all participants (≥20 years old) with baseline measurements of IgA, IgG or IgM (n = 41,900, 136,221, and 29,919, respectively). Participants were excluded if they had a history of chronic pancreatitis and individuals were free from pancreatic cancer at baseline. Multivariate Cox proportional hazards regression was used to estimate risk of pancreatic cancer for medical cut-offs of IgA, IgG, and IgM. Results: Compared to the reference level of 6.10–14.99 g/L, risk of pancreatic cancer was elevated among those with IgG levels <6.10 g/L [HR: 1.69 (95% CI 0.99–2.87)], and an inverse association was observed among those with IgG levels ≥15.00 g/L [0.82 (95% CI 0.64–1.05); Ptrend = 0.027]. The association appeared to be stronger for women than men [HR: 0.64 (95% CI 0.43–0.97) and 0.95 (95% CI 0.69–1.29), respectively]. No associations were observed with IgA or IgM. Conclusion: An inverse association was observed between pre-diagnostic serum levels of IgG and risk of pancreatic cancer. Our findings highlight the need to further investigate the role of immune response in pancreatic cancer etiology.

AB - Background: Emerging evidence points to potential roles of the humoral immune responses in the development of pancreatic cancer. Epidemiological studies have suggested involvement of viral and bacterial infections in pancreatic carcinogenesis. Experimental studies have reported high expression levels of antigens in pancreatic cancer cells. Therefore, we aimed to investigate the role of different components of humoral immunity in the context of pancreatic cancer. We evaluated associations between pre-diagnostic serum markers of the overall humoral immune system [immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM)], and the risk of pancreatic cancer in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) study. Methods: We selected all participants (≥20 years old) with baseline measurements of IgA, IgG or IgM (n = 41,900, 136,221, and 29,919, respectively). Participants were excluded if they had a history of chronic pancreatitis and individuals were free from pancreatic cancer at baseline. Multivariate Cox proportional hazards regression was used to estimate risk of pancreatic cancer for medical cut-offs of IgA, IgG, and IgM. Results: Compared to the reference level of 6.10–14.99 g/L, risk of pancreatic cancer was elevated among those with IgG levels <6.10 g/L [HR: 1.69 (95% CI 0.99–2.87)], and an inverse association was observed among those with IgG levels ≥15.00 g/L [0.82 (95% CI 0.64–1.05); Ptrend = 0.027]. The association appeared to be stronger for women than men [HR: 0.64 (95% CI 0.43–0.97) and 0.95 (95% CI 0.69–1.29), respectively]. No associations were observed with IgA or IgM. Conclusion: An inverse association was observed between pre-diagnostic serum levels of IgG and risk of pancreatic cancer. Our findings highlight the need to further investigate the role of immune response in pancreatic cancer etiology.

KW - AMORIS

KW - IgA

KW - IgG

KW - IgM

KW - immune system and cancer

KW - pancreatic cancer

KW - serum immunoglobulin

UR - http://www.scopus.com/inward/record.url?scp=85082714911&partnerID=8YFLogxK

U2 - 10.3389/fonc.2020.00263

DO - 10.3389/fonc.2020.00263

M3 - Article

C2 - 32185133

SN - 2234-943X

VL - 10

SP - 263

JO - Frontiers in oncology

JF - Frontiers in oncology

M1 - 263

ER -

Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this